DESCRIPTION OF THE RESULTS OF A COMPARATIVE STUDY OF IMMUNOGLOBULIN CONTENT IN THE SERUM OF WOMEN WITH PRE-CERVICAL TUMOR
Keywords:
immunoglobulin, humoral immunity, biological marker, humoral factor, plasma cellsAbstract
The study examined changes in serum immunoglobulins in women with precancerous cervical lesions. Cervical cancer in women is characterized by a severe course, poor treatment efficacy, and often fatal outcome. Precancerous cervical diseases have been proven to be among the main risk factors for this medical and socio-economic problem[1]. Therefore, it is advisable to have biological markers and clinical laboratory criteria that clearly identify the disease. Taking into account the above, this study aimed to conduct a comparative investigation of the serum concentrations of humoral immune factors in women with precancerous cervical conditions.
References
Gizinger O.A. Immunomodulation in gynecology. Opinions of an immunologist and an obstetrician-gynecologist. Practical questions of colposcopy // Genital Infections. – 2022. – No.2. – P.18-23.
Abakumova T.V., Myagdieva I.R., Dolgova D.R., Gening S.O., Antoneyeva I.I., Gening T.P. IL-4 and its polymorphism (IL4-589C/T) in cervical neoplasia // Medical Immunology. – 2023. – Vol.25, No.5. – P.1129-1134.
Belyavskaya V.A., Cherdyntseva N.V., Kzyszkovska Yu.G., Litvyakov N.V. Microbiome, immune system and cancer: three sides of the same medal // Siberian Oncological Journal. – 2022. – No.21(6). – P.131-144.
Ikhtiyarova G.A., Navruzova N.O., Karimova G.K. Modern diagnostic methods for early detection of cervical diseases // Doktor Axborotnomasi. – 2019. – No.4. – P.78-80.
Mazitova M.I., Bikineev M.S. Stages of cytological screening for cervical cancer // R.M.J. Mother and Child. – 2019. – Vol.2, No.4. – P.322-326.
Loginova O.P., Shevchenko N.I., Gasich E.L. Peculiarities of local vaginal immunity in HPV-negative cervical dysplasia // Medical-Biological Science News. – 2025. – Vol.25, No.3. – P.230-239.
Mamedov U.S., Mirakhmedova S.S. Dynamics of women’s immune status during cervical HPV treatment // Bulletin of Science and Education. – 2020. – No.24(102), Pt.3. – P.81-84.
Semiglazov V.F., Tseluyko A.I., Balduyeva I.A., Nekhaeva T.L., Artemieva A.S., Kudaybergenova A.G. et al. Immunology and immunotherapy in combined treatment of malignant tumors // Medical Council. – 2021. – No.4. – P.248-257.
Petrov Yu.A., Blesmanovich A.E., Bagnovskaya A.G. From background processes to cervical cancer: causes, diagnosis, and prevention // Glavvrach of South Russia. – 2020. – Vol.74, No.4. – P.36-39.
Zhen S., Lu J., Liu Y.-H., Chen W., Li X. Synergistic antitumor effect on cervical cancer by rational combination of PD-1 blockade and CRISPR-Cas9-mediated HPV knockout // Cancer Gene Therapy. – 2019. – Vol.27. – P.168-178.
